Savara is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara’s pipeline comprises: Molgradex, a Phase 3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF; AeroVanc, a Phase 3 ready inhaled vancomycin, and Aironite, a Phase 2 stage inhaled sodium nitrite.
Molgradex for PAP
Molgradex is the first treatment being developed for inhalation of GM-CSF for the treatment of patients suffering from a rare respiratory disease called pulmonary alveolar proteinosis (PAP).
AeroVanc for CF
AeroVanc is the first inhaled antibiotic being developed to address the growing problem of chronic methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF).